Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Cardiovascular–kidney–metabolic risk stratification and cardiorenal outcomes with SGLT2 inhibitors versus GLP-1 receptor agonists in type 2 diabetes: a global federated network study

A consistent cardiorenal benefit pattern was observed across low, moderate and high CKM strata, with SGLT2i reducing renal outcomes and GLP-1RA conferring greater cardiovascular protection.

C. Wang, A. Askarinejad, Y. Chen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.